Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Andrzej Pilc, Agata Machaczka, Paweł Kawalec, Jodi L. Smith & Jeffrey M. Witkin. (2022) Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opinion on Drug Discovery 17:10, pages 1131-1146.
Read now
Read now
Anees Bahji, Carlos A. Zarate & Gustavo H. Vazquez. (2022) Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opinion on Drug Safety 21:6, pages 853-866.
Read now
Read now
Laura Perez-Caballero, Victor Perez & Esther Berrocoso. (2020) What ketamine can teach us about the opioid system in depression?. Expert Opinion on Drug Discovery 15:12, pages 1369-1372.
Read now
Read now
Jennifer Swainson, Rejish K Thomas, Shaina Archer, Carson Chrenek, Mary-Anne MacKay, Glen Baker, Serdar Dursun, Larry J. Klassen, Pratap Chokka & Michael L Demas. (2019) Esketamine for treatment resistant depression. Expert Review of Neurotherapeutics 19:10, pages 899-911.
Read now
Read now
Articles from other publishers (72)
Rika Takaba, Daisuke Ibi, Keisuke Yoshida, Eri Hosomi, Ririna Kawase, Hiroko Kitagawa, Hirotaka Goto, Mizuki Achiwa, Kento Mizutani, Kyosuke Maede, Javier González-Maeso, Shinji Kitagaki & Masayuki Hiramatsu. (2023) Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Henrik Weber, Nils Drouvé, Lana Kortenbrede & Sherif El Sheikh. (2023) A Broadly Applicable Diels–Alder-Based Synthesis of Ketamine-Related Arylcyclohexylamines. The Journal of Organic Chemistry 88:15, pages 11372-11376.
Crossref
Crossref
Li Ma, Long Wang, Youge Qu, Xiayun Wan & Kenji Hashimoto. (2023) A role of splenic heme biosynthesis pathway in the persistent prophylactic actions of arketamine in lipopolysaccharide-treated mice. Translational Psychiatry 13:1.
Crossref
Crossref
Simin Ye, Yanqiang Han, Zhiyun Wei & Jinjin Li. (2023) Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors. Molecules 28:11, pages 4346.
Crossref
Crossref
Dominika Kobus‐Bartoszewicz & Sebastian Stecko. (2023) Synthesis of Chiral α‐Amino Ketones via Transition Metal Catalyzed or Photoredox Cross‐Coupling and Olefin Photo‐Cleavage Reaction Sequence. Advanced Synthesis & Catalysis 365:8, pages 1224-1237.
Crossref
Crossref
Bhuvi Sachdeva, Punya Sachdeva, Shampa Ghosh, Faizan Ahmad & Jitendra Kumar Sinha. (2023) Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects. Ibrain 9:1, pages 90-101.
Crossref
Crossref
Kai Zhang, Yitan Yao & Kenji Hashimoto. (2023) Ketamine and its metabolites: Potential as novel treatments for depression. Neuropharmacology 222, pages 109305.
Crossref
Crossref
Nidhi Awasthi, Rolly Yadav & Devesh Kumar. (2023) Revealing metabolic path of Ketamine catalyzed by CYP450 via quantum mechanical approach. Journal of Molecular Structure 1271, pages 134126.
Crossref
Crossref
Li Ma, Long Wang, Lijia Chang, Jiajing Shan, Youge Qu, Xingming Wang, Yuko Fujita & Kenji Hashimoto. (2022) A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model. Neuropharmacology 219, pages 109250.
Crossref
Crossref
Ji-chun Zhang, Wei Yao & Kenji Hashimoto. (2022) Arketamine, a new rapid-acting antidepressant: A historical review and future directions. Neuropharmacology 218, pages 109219.
Crossref
Crossref
Sanne Y Smith-Apeldoorn, Jolien KE Veraart, Jan Spijker, Jeanine Kamphuis & Robert A Schoevers. (2022) Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. The Lancet Psychiatry 9:11, pages 907-921.
Crossref
Crossref
Li Ma, Long Wang, Lijia Chang, Jiajing Shan, Youge Qu, Xingming Wang, Xiayun Wan, Yuko Fujita & Kenji Hashimoto. (2022) A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice. Translational Psychiatry 12:1.
Crossref
Crossref
Cigdem Yildirim Guclu. 2022. Ketamine Revisited - New Insights into NMDA Inhibitors. Ketamine Revisited - New Insights into NMDA Inhibitors.
Xiayun Wan, Akifumi Eguchi, Yuko Fujita, Li Ma, Xingming Wang, Yong Yang, Youge Qu, Lijia Chang, Jiancheng Zhang, Chisato Mori & Kenji Hashimoto. (2022) Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: A role of gut microbiota. Neuropharmacology 213, pages 109139.
Crossref
Crossref
Xingming Wang, Jianjun Yang & Kenji Hashimoto. (2022) (R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression. Neuroscience & Biobehavioral Reviews 139, pages 104762.
Crossref
Crossref
Li Ren, Hailou Zhang, Weiwei Tao, Yin Chen, Zhilu Zou, XiaoYan Guo, Qinqin Shen, Quansheng Feng & Jingqing Hu. (2022) The Rapid and Long-Lasting Antidepressant Effects of Iridoid Fraction in Gardenia Jasminoides J.Ellis Are Dependent on Activating PKA-CREB Signaling Pathway. Frontiers in Pharmacology 13.
Crossref
Crossref
Yunfei Tan, Yuko Fujita, Yaoyu Pu, Lijia Chang, Youge Qu, Xinming Wang & Kenji Hashimoto. (2022) Repeated intermittent administration of (R)-ketamine during juvenile and adolescent stages prevents schizophrenia-relevant phenotypes in adult offspring after maternal immune activation: a role of TrkB signaling. European Archives of Psychiatry and Clinical Neuroscience 272:4, pages 693-701.
Crossref
Crossref
Xingming Wang, Lijia Chang, Xiayun Wan, Yunfei Tan, Youge Qu, Jiajing Shan, Yong Yang, Li Ma & Kenji Hashimoto. (2022) (R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: A role of gut–microbiota–brain axis. Neurobiology of Disease 165, pages 105635.
Crossref
Crossref
María Eugenia Riveros, Alba Ávila, Koen Schruers & Fernando Ezquer. (2022) Antioxidant Biomolecules and Their Potential for the Treatment of Difficult-to-Treat Depression and Conventional Treatment-Resistant Depression. Antioxidants 11:3, pages 540.
Crossref
Crossref
Wei Yao, Qianqian Cao, Shilin Luo, Lujuan He, Chun Yang, Jiaxu Chen, Qi Qi, Kenji Hashimoto & Ji-chun Zhang. (2021) Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Molecular Psychiatry 27:3, pages 1618-1629.
Crossref
Crossref
Kai Zhang, Yating Yang, Xiaoping Yuan, Wenjun Zhang, Xu Han, Chengwen Lei, Zhiguo Tao, Yuanhai Li & Huanzhong Liu. (2022) Efficacy and safety of repeated esketamine intravenous infusion in the treatment of treatment-resistant depression: A case series. Asian Journal of Psychiatry 68, pages 102976.
Crossref
Crossref
Li Ma, Jiancheng Zhang, Yuko Fujita, Youge Qu, Jiajing Shan, Xiayun Wan, Xingming Wang, Tamaki Ishima, Kenta Kobayashi, Long Wang & Kenji Hashimoto. (2022) Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine. Translational Psychiatry 12:1.
Crossref
Crossref
Atamjit Singh & Preet Mohinder Singh Bedi. 2022. Ketamine Revisited - New Insights into NMDA Inhibitors [Working Title]. Ketamine Revisited - New Insights into NMDA Inhibitors [Working Title].
Yan Wei, Lijia Chang & Kenji Hashimoto. (2021) Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Molecular Psychiatry 27:1, pages 559-573.
Crossref
Crossref
Chao Dong, Zheng Tian, Yuko Fujita, Atsuhiro Fujita, Noriko Hino, Michihiko Iijima & Kenji Hashimoto. (2022) Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram. Pharmacology Biochemistry and Behavior 212, pages 173316.
Crossref
Crossref
Bijia Song & Jun-Chao Zhu. (2021) Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review. Frontiers in Pharmacology 12.
Crossref
Crossref
Xingming Wang, Lijia Chang, Yunfei Tan, Youge Qu, Jiajing Shan & Kenji Hashimoto. (2021) (R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice. Brain Research Bulletin 177, pages 316-323.
Crossref
Crossref
Jordi Bonaventura, Sherry Lam, Meghan Carlton, Matthew A. Boehm, Juan L. Gomez, Oscar Solís, Marta Sánchez-Soto, Patrick J. Morris, Ida Fredriksson, Craig J. Thomas, David R. Sibley, Yavin Shaham, Carlos A. ZarateJrJr & Michael Michaelides. (2021) Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Molecular Psychiatry 26:11, pages 6704-6722.
Crossref
Crossref
Lucas Araújo-de-Freitas, Cassio Santos-Lima, Euclides Mendonça-Filho, Flávia Vieira, Ricardo J A F França, Guilherme Magnavita, Tanise L Cardoso, Fernanda S Correia-Melo, Gustavo C Leal, Ana Paula Jesus-Nunes, Breno Souza-Marques, Roberta Marback, Manuela Teles, Mariana VF Echegaray, Graziele Beanes, Lívia N F Guerreiro-Costa, Rodrigo P Mello, Thaís Rabanea, Ana Cecília Lucchese, Neander Abreu, Acioly L T Lacerda & Lucas C Quarantini. (2021) Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study. Psychiatry Research 303, pages 114058.
Crossref
Crossref
Ya-Ting Wang, Xiao-Le Wang, Si-Tong Feng, Nai-Hong Chen, Zhen-Zhen Wang & Yi Zhang. (2021) Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression. Pharmacological Research 171, pages 105761.
Crossref
Crossref
Yan Wei, Lijia Chang & Kenji Hashimoto. (2021) Intranasal administration of transforming growth factor-β1 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: A role of TrkB signaling. European Neuropsychopharmacology 50, pages 55-63.
Crossref
Crossref
Ariana Pérez-Pereira, Alexandra Maia, Virgínia Gonçalves, Cláudia Ribeiro & Maria Elizabeth Tiritan. (2021) Enantioselective Monitoring of Biodegradation of Ketamine and Its Metabolite Norketamine by Liquid Chromatography. Chemosensors 9:9, pages 242.
Crossref
Crossref
Yuko Fujita, Yaeko Hashimoto, Hiroyo Hashimoto, Lijia Chang & Kenji Hashimoto. (2021) Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: A role of TrkB signaling. European Journal of Pharmacology 897, pages 173954.
Crossref
Crossref
Youge Qu, Jiajing Shan, Siming Wang, Lijia Chang, Yaoyu Pu, Xingming Wang, Yunfei Tan, Masayuki Yamamoto & Kenji Hashimoto. (2020) Rapid-acting and long-lasting antidepressant-like action of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling. European Archives of Psychiatry and Clinical Neuroscience 271:3, pages 439-446.
Crossref
Crossref
Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia-Melo, Manuela Telles, Rodrigo P. Mello, Flavia Vieira, Cassio S. Lima, Ana Paula Jesus-Nunes, Lívia N. F. Guerreiro-Costa, Roberta F. Marback, Ana Teresa Caliman-Fontes, Breno L. S. Marques, Marília L. O. Bezerra, Alberto L. Dias-Neto, Samantha S. Silva, Aline S. Sampaio, Gerard Sanacora, Gustavo Turecki, Colleen Loo, Acioly L. T. Lacerda & Lucas C. Quarantini. (2020) Intravenous arketamine for treatment-resistant depression: open-label pilot study. European Archives of Psychiatry and Clinical Neuroscience 271:3, pages 577-582.
Crossref
Crossref
Kai Zhang, Gang Jia, Lei Xia, Jianbin Du, Guanchen Gai, Zhiqiang Wang, Leiming Cao, Fuquan Zhang, Rui Tao, Huanzhong Liu, Kenji Hashimoto & Guoqiang Wang. (2020) Efficacy of anticonvulsant ethosuximide for major depressive disorder: a randomized, placebo-control clinical trial. European Archives of Psychiatry and Clinical Neuroscience 271:3, pages 487-493.
Crossref
Crossref
Kai Zhang, Akemi Sakamoto, Lijia Chang, Youge Qu, Siming Wang, Yaoyu Pu, Yunfei Tan, Xingming Wang, Yuko Fujita, Tamaki Ishima, Masahiko Hatano & Kenji Hashimoto. (2019) Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine. European Archives of Psychiatry and Clinical Neuroscience 271:3, pages 447-456.
Crossref
Crossref
Anees Bahji, Gustavo H. Vazquez & Carlos A. ZarateJrJr. (2021) Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?. Journal of Affective Disorders 282, pages 258-260.
Crossref
Crossref
Kenji Hashimoto. (2021) Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. European Archives of Psychiatry and Clinical Neuroscience 271:2, pages 249-258.
Crossref
Crossref
Priti Jain, Shreyans K. Jain & Munendra Jain. (2021) Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. Current Molecular Medicine 21:2, pages 111-132.
Crossref
Crossref
Qingzhong Wang & Yogesh Dwivedi. (2021) Advances in novel molecular targets for antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 104, pages 110041.
Crossref
Crossref
Anees Bahji, Gustavo H. Vazquez & Carlos A. ZarateJrJr. (2021) Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders 278, pages 542-555.
Crossref
Crossref
Kai Zhang & Kenji Hashimoto. 2021. The Neuroscience of Depression. The Neuroscience of Depression
393
399
.
Yunfei Tan & Kenji Hashimoto. 2021. New Rapid-acting Antidepressants. New Rapid-acting Antidepressants
31
48
.
Kai Zhang & Kenji Hashimoto. 2021. New Rapid-acting Antidepressants. New Rapid-acting Antidepressants
1
16
.
Yuko Fujita & Kenji Hashimoto. (2020)
Decreased bone mineral density in ovariectomized mice is ameliorated after subsequent repeated intermittent administration of (
R
)‐ketamine, but not (
S
)‐ketamine
. Neuropsychopharmacology Reports 40:4, pages 401-406.
Crossref
Crossref
Joydip Das. (2020) Repurposing of Drugs–The Ketamine Story. Journal of Medicinal Chemistry 63:22, pages 13514-13525.
Crossref
Crossref
Kenji Hashimoto. (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochemical Pharmacology 177, pages 113935.
Crossref
Crossref
Paola Rodrı́guez, Jessika Urbanavicius, José Pedro Prieto, Sara Fabius, Ana Laura Reyes, Vaclav Havel, Dalibor Sames, Cecilia Scorza & Ignacio Carrera. (2020) A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats. ACS Chemical Neuroscience 11:11, pages 1661-1672.
Crossref
Crossref
Yunfei Tan & Kenji Hashimoto. (2020) Risk of psychosis after repeated intermittent administration of (S)-ketamine, but not (R)-ketamine, in mice. Journal of Affective Disorders 269, pages 198-200.
Crossref
Crossref
Zhongwei Xiong, Lijia Chang, Youge Qu, Yaoyu Pu, Siming Wang, Yuko Fujita, Tamaki Ishima, Jincao Chen & Kenji Hashimoto. (2020) Neuronal brain injury after cerebral ischemic stroke is ameliorated after subsequent administration of (R)-ketamine, but not (S)-ketamine. Pharmacology Biochemistry and Behavior 191, pages 172904.
Crossref
Crossref
Flavia R. Carreno, Daniel J. Lodge & Alan Frazer. (2020) Ketamine: Leading us into the future for development of antidepressants. Behavioural Brain Research 383, pages 112532.
Crossref
Crossref
Yan Wei, Lijia Chang & Kenji Hashimoto. (2020) A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacology Biochemistry and Behavior 190, pages 172870.
Crossref
Crossref
Lijia Chang, Kai Zhang, Yaoyu Pu, Youge Qu, Si-ming Wang, Zhongwei Xiong, Yukihiko Shirayama & Kenji Hashimoto. (2019) Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model. European Archives of Psychiatry and Clinical Neuroscience 270:2, pages 271-275.
Crossref
Crossref
Jiancheng Zhang, Yuko Fujita, Lijia Chang, Yaoyu Pu, Youge Qu, Siming Wang & Kenji Hashimoto. (2020) Beneficial effects of anti-RANKL antibody in depression-like phenotype, inflammatory bone markers, and bone mineral density in male susceptible mice after chronic social defeat stress. Behavioural Brain Research 379, pages 112397.
Crossref
Crossref
Kai Zhang, Chun Yang, Lijia Chang, Akemi Sakamoto, Toru Suzuki, Yuko Fujita, Youge Qu, Siming Wang, Yaoyu Pu, Yunfei Tan, Xingming Wang, Tamaki Ishima, Yukihiko Shirayama, Masahiko Hatano, Kenji F. Tanaka & Kenji Hashimoto. (2020) Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. Translational Psychiatry 10:1.
Crossref
Crossref
David Dadiomov. (2020) Dissociating the Clinical Role and Economic Value of Intranasal Esketamine. Journal of Managed Care & Specialty Pharmacy 26:1, pages 20-22.
Crossref
Crossref
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, Atul Khullar, Mary-Anne MacKay, Glen B. Baker & Serdar M. Dursun. (2020) Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Therapeutic Advances in Psychopharmacology 10, pages 204512532091665.
Crossref
Crossref
Neil McNaughton. (2020) Personality neuroscience and psychopathology: should we start with biology and look for neural-level factors?. Personality Neuroscience 3.
Crossref
Crossref
N. McNaughton & P. Glue. (2020) Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders. Personality Neuroscience 3.
Crossref
Crossref
C. Gastaldon, D. Papola, G. Ostuzzi & C. Barbui. (2019) Esketamine for treatment resistant depression: a trick of smoke and mirrors?. Epidemiology and Psychiatric Sciences 29.
Crossref
Crossref
Yunfei Tan, Yuko Fujita, Youge Qu, Lijia Chang, Yaoyu Pu, Siming Wang, Xingming Wang & Kenji Hashimoto. (2020) Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling. Pharmacology Biochemistry and Behavior 188, pages 172839.
Crossref
Crossref
Lushan Yu & Su Zeng. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters
461
485
.
Atsuhiro Fujita, Yuko Fujita, Yaoyu Pu, Lijia Chang & Kenji Hashimoto. (2019) MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. Psychopharmacology 237:1, pages 83-92.
Crossref
Crossref
Lijia Chang, Yan Wei & Kenji Hashimoto. 2020. Ketamine. Ketamine
105
125
.
Chun Yang, Jianjun Yang, Ailin Luo & Kenji Hashimoto. (2019) Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Translational Psychiatry 9:1.
Crossref
Crossref
Jack Williams Shteamer, Mayson Augustus Callaway, Parth Patel & Vinita Singh. (2019) How effective is ketamine in the management of chronic neuropathic pain?. Pain Management 9:6, pages 517-519.
Crossref
Crossref
Kenji Hashimoto. (2019) Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry and Clinical Neurosciences 73:10, pages 613-627.
Crossref
Crossref
Jiancheng Zhang, Youge Qu, Lijia Chang, Yaoyu Pu & Kenji Hashimoto. (2019) (R)-Ketamine Rapidly Ameliorates the Decreased Spine Density in the Medial Prefrontal Cortex and Hippocampus of Susceptible Mice After Chronic Social Defeat Stress. International Journal of Neuropsychopharmacology 22:10, pages 675-679.
Crossref
Crossref
Carla Vitorino, Soraia Silva, Joana Bicker, Amílcar Falcão & Ana Fortuna. (2019) Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. Drug Discovery Today 24:9, pages 1911-1923.
Crossref
Crossref
Zhongwei Xiong, Yuko Fujita, Kai Zhang, Yaoyu Pu, Lijia Chang, Min Ma, Jincao Chen & Kenji Hashimoto. (2019) Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model. Behavioural Brain Research 368, pages 111904.
Crossref
Crossref
Lijia Chang, Kai Zhang, Yaoyu Pu, Youge Qu, Si-ming Wang, Zhongwei Xiong, Qian Ren, Chao Dong, Yuko Fujita & Kenji Hashimoto. (2019) Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacology Biochemistry and Behavior 181, pages 53-59.
Crossref
Crossref